US Department of Health and Human Services, National Vaccine Program Office, 200 Independence Ave SW, Room 717H, Washington, DC 20201-0004, USA.
Pediatrics. 2009 Dec;124 Suppl 5:S540-7. doi: 10.1542/peds.2009-1542N.
The goal was to understand vaccine manufacturers' perspectives on vaccine financing as a barrier to immunization.
Individual telephone interviews with representatives of the 6 manufacturers that produce routinely recommended vaccines for children and adolescents in the United States were conducted in November and December 2006.
Although manufacturers acknowledged that the price of newer vaccines presents challenges to optimal vaccine use, they asserted that children and adolescents have access to vaccinations through public and private insurance. Respondents suggested that the system could be improved through adequate funding of the public-sector safety net. Respondents stated that providers should receive timely reimbursement for the full costs of vaccine purchase and administration, and manufacturers who sell directly to health care providers may provide flexible payment terms for vaccine purchases. Manufacturers supported targeted expansion of the Vaccines for Children program to allow children with incomplete insurance coverage for vaccines to receive vaccines at health department clinics. Manufacturers perceived delays in publication of Advisory Committee on Immunization Practices recommendations as a potential barrier to vaccine uptake. They viewed the perceived lack of public value for vaccines as a potential barrier to adequate reimbursement and optimal utilization. Respondents also maintained that their ability to negotiate vaccine prices through the private market is a crucial priority.
Manufacturers assert that children and adolescents have access to immunizations through public and private insurance. Manufacturers think that they have mitigated the challenge most directly in their control: the large financial outlays required for up-front vaccine purchases.
了解疫苗制造商对疫苗融资作为免疫障碍的看法。
2006 年 11 月至 12 月，对在美国为儿童和青少年常规推荐疫苗的 6 家制造商的代表进行了个人电话访谈。
尽管制造商承认较新疫苗的价格对最佳疫苗使用构成了挑战，但他们坚持认为儿童和青少年可以通过公共和私人保险获得疫苗。受访者表示，可以通过为公共部门安全网提供充足资金来改善该系统。受访者表示，提供者应及时获得疫苗购买和管理的全部费用的报销，直接向医疗保健提供者销售的制造商可能为疫苗购买提供灵活的付款条件。制造商支持有针对性地扩大儿童疫苗计划，以使那些不完全有疫苗保险的儿童能够在卫生部门诊所接种疫苗。制造商认为，免疫实践咨询委员会建议的延迟发布可能是疫苗接种延迟的潜在障碍。他们认为，公众对疫苗缺乏价值感是充分补偿和最佳利用的潜在障碍。受访者还认为，他们通过私人市场协商疫苗价格的能力是一个关键优先事项。
制造商声称，儿童和青少年可以通过公共和私人保险获得免疫接种。制造商认为，他们已经在最直接影响他们的方面缓解了这一挑战：即前期疫苗购买所需的大量资金支出。
